Navigation Links
Keryx Biopharmaceuticals, Inc. Announces First Quarter 2012 Financial Results
Date:5/8/2012

al cancer, we remain excited by the prospects of the Zerenex opportunity as a treatment for hyperphosphatemia.  Following two successful short-term Phase 3 studies of Zerenex, in the U.S. and Japan, we look forward to the completion of the Phase 3 clinical programs in the U.S. and Japan by year-end, and the potential New Drug Application filings in the U.S., Europe and Japan within less than  twelve months."  Ron Bentsur, continued, "Our financial position remains strong and we believe that we have sufficient capital to take us beyond the anticipated NDA filings for Zerenex."

The Company will host an investor conference call tomorrow, Wednesday, May 9, 2012, at 8:30am EDT, to discuss the Company's first quarter financial results and provide a business outlook for the remainder of 2012.In order to participate in the conference call, please call 1-877-869-3847 (U.S.), 1-201-689-8261 (outside the U.S.), call-in ID: KERYX. The audio recording of the conference call will be available for replay at http://www.keryx.com, for a period of 15 days after the call.
ABOUT KERYX BIOPHARMACEUTICALS, INC.Keryx Biopharmaceuticals is focused on the acquisition, development and commercialization of medically important pharmaceutical products for the treatment of renal disease. Keryx is developing Zerenex (ferric citrate), an oral, ferric iron-based compound that has the capacity to bind to phosphate and form non-absorbable complexes. The Phase 3 clinical program of Zerenex for the treatment of hyperphosphatemia (elevated phosphate levels) in patients with end-stage renal disease is being conducted pursuant to a Special Protocol Assessment (SPA) agreement with the FDA. Keryx is headquartered in New York City.

Cautionary StatementSome of the statements included in this press release, particularly those anticipating future clinical trials and business prospects for Zerenex (ferric citrate) may be forward-looking
'/>"/>

SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Keryx Biopharmaceuticals to Present at William Blair & Company Small-Cap Growth Stock Conference
2. Keryx Biopharmaceuticals, Inc. Announces Positive Preliminary Phase 2 Data on KRX-0401 in Patients with Chemo-Insensitive Rare Sarcoma
3. Keryx Biopharmaceuticals, Inc. Announces Phase 1 and Phase 2 Data on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Multiple Myeloma at 49th Annual Meeting of American Society of Hematology
4. Keryx Biopharmaceuticals Completes SUN-MICRO Phase 3 Pivotal Trial
5. Keryx Biopharmaceuticals Announces that the SUN-MICRO Phase 3 Clinical Trial Failed to Meet its Primary Efficacy Endpoint
6. Keryx Biopharmaceuticals Announces Termination of SUN-MACRO Phase 4 Trial
7. Keryx Biopharmaceuticals, Inc. Announces Poster Presentation Highlighting Observed Clinical Activity of KRX-0401 (Perifosine) at the American Society of Clinical Oncology Meeting in Chicago, Illinois
8. Keryx Biopharmaceuticals, Inc. Announces Phase 2 Results on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Waldenstroms Macroglobulinemia at the 44th Annual Meeting of the American Society of Clinical Oncology
9. Keryx Biopharmaceuticals, Inc. Reports Phase 1/2 Data on KRX-0401 (Perifosine) at 50th Annual Meeting of American Society of Hematology
10. Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data on KRX-0401 (Perifosine) in Combination with Bortezomib (+/- Dexamethasone) at the 12th International Multiple Myeloma Meeting
11. Keryx Biopharmaceuticals Reports Single Agent Phase 2 Data of KRX-0401 (Perifosine) Further Demonstrating KRX-0401s Activity in the Treatment of Advanced Metastatic Renal Cell Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2014)... Sept. 22, 2014 China Nepstar Chain Drugstore Ltd. (NYSE: ... drugstore chain in China based on the ... its 2014 Annual General Meeting of Shareholders (the "AGM") on October ... held at the meeting room of the Company at 6th Floor, ... , Guangdong Province 518054, ...
(Date:9/19/2014)... A pharmaceutical executive in the market research ... he wanted the research and consulting firm to explore: ... for secondary research) to maximize efficiency and maintain a ... , Automation of market research processes for efficient ... to implement and manage those automated systems ...
(Date:9/19/2014)... 19, 2014 /PRNewswire-iReach/ -- Market Research Report ... 2009-2019 is a professional and in-depth market ... industry. The report firstly reviews the basic ... application and manufacturing technology. The report then ... Oxybutynin Hydrochloride listing their product specification, capacity, ...
Breaking Medicine Technology:China Nepstar Chain Drugstore Schedules Annual General Meeting of Shareholders for October 22, 2014 2In Era of Competing Needs, Market Research Groups Under Pressure to Utilize Automation and External Staffing 2Oxybutynin Hydrochloride Industry 2014-2019 Chinese Forecasts & Analysis 2Oxybutynin Hydrochloride Industry 2014-2019 Chinese Forecasts & Analysis 3Oxybutynin Hydrochloride Industry 2014-2019 Chinese Forecasts & Analysis 4Oxybutynin Hydrochloride Industry 2014-2019 Chinese Forecasts & Analysis 5
... Cosmetic Surgery hopes to raise awareness of some of the ... cosmetic surgery industry through the launch of a series of ... on the subject, such as question and answer sessions, conferences ... new initiatives online, that it hopes people from all over ...
... PINE BROOK, N.J., Oct. 24, 2011 Elusys Therapeutics, ... of antibody therapeutics, announced today that it is initiating ... of Anthim (ETI-204), the company,s anti-toxin in late-stage development ... inhaled anthrax. The company also announced it has successfully ...
Cached Medicine Technology:Liberate Cosmetic Surgery aims to Highlight Cosmetic Surgery Industry Issues 2Elusys Initiates Third Clinical Safety Study of Anthim, a New Anthrax Treatment; Company Successfully Completes Manufacturing at Commercial Scale 2Elusys Initiates Third Clinical Safety Study of Anthim, a New Anthrax Treatment; Company Successfully Completes Manufacturing at Commercial Scale 3
(Date:9/22/2014)... SANTA CLARA, Calif.– Health 2.0 8th ... Healthline , a leading provider of intelligent ... HealthData Engine to harness the power ... and reduce costs. The new big data analytics ... advanced clinical natural language processing (NLP) technologies and ...
(Date:9/22/2014)... 22, 2014 The Advocator Group, LLC— ... its partnership with the RxCut® pharmacy savings program, which ... and employees. The company looks forward to offering prescription ... the ways in which they deliver on the goal ... by Free For All® Inc., the RxCut® ...
(Date:9/22/2014)... Tristar Products, Inc. is celebrating the ... known as the 'Godfather of Fitness,' with the release ... September 24th at the TriBeCa Film Center® in New ... behind the man whose mission was to show the ... The name of the film is derived from one ...
(Date:9/22/2014)... estimated 1.68 to 3.8 million sports-related concussions occur in ... a significant number that go unreported. Current Concepts ... of Neurosurgery , official journal of ... Gail Rosseau, MD, the lead guest editor, is well ... prevention, and serves on the Board of Directors of ...
(Date:9/22/2014)... Research reveals that the body’s supply ... declines during the aging process. This decline allows the ... as wrinkles, droopy skin, weakened muscles and loss of ... Growth Hormone (GH) Secretion and Insulin-Like Growth Factor I ... the aging process. , Decades of scientific research ...
Breaking Medicine News(10 mins):Health News:Healthline’s New HealthData Engine Turns Unstructured Data Into Actionable Insights 2Health News:Healthline’s New HealthData Engine Turns Unstructured Data Into Actionable Insights 3Health News:Healthline’s New HealthData Engine Turns Unstructured Data Into Actionable Insights 4Health News:Healthline’s New HealthData Engine Turns Unstructured Data Into Actionable Insights 5Health News:The Advocator Group, LLC Announces Partnership with Pharmacy Savings Program RxCut® 2Health News:The Advocator Group, LLC Announces Partnership with Pharmacy Savings Program RxCut® 3Health News:Tristar Products Premieres The Jack LaLanne Documentary at TriBeCa Film Center in New York City 2Health News:Tristar Products Premieres The Jack LaLanne Documentary at TriBeCa Film Center in New York City 3Health News:Neurosurgery tackles past, current and future concepts of sports concussion 2Health News:Neurosurgery tackles past, current and future concepts of sports concussion 3Health News:Neurosurgery tackles past, current and future concepts of sports concussion 4Health News:Diet Doc Reveals the Secret to Looking and Feeling Younger with new Prescription Sermorelin hGH Anti-Aging Therapy 2Health News:Diet Doc Reveals the Secret to Looking and Feeling Younger with new Prescription Sermorelin hGH Anti-Aging Therapy 3
... New Zealanders and mild deficiency in some parts of ... New Zealand (FSANZ) to consider a proposal to replace ... products. Recent studies had shown that Australians, particularly ... ,The proposal by FSANZ is aimed at reducing iodine ...
... in Cambodia have now been affected by bird flu killing ... after a man smuggled infected ducks in from Vietnam. ... as telling Reuters that two people were admitted to the ... in Prey Veng province around 1,300 ducks died from bird ...
... milestone in the mapping of the bovine genome, which will ... disease// control in cattle. This research is slated to benefit ... up on a sequence of 2.9 million DNA base pairs, ... in one pair, which can alter the productivity of the ...
... paint has been created by scientists at Cornell University ... ,This edible paint made by creating colored calcium alginate ... has a wide range of applications, including food and ... that, although the technology was originally developed for non-food ...
... initial clinical trials show that China’s first AIDS vaccine ... people who received the injections showed no severe adverse ... said Zhang Wei, head of the pharmaceutical registration department ... ,"The recipients appeared immune to the HIV-1 virus ...
... ten years back from a graveyard has led police to believe ... ,The missing of the corpse came to light only ... being hit by lightning, complained that his body had gone missing ... family used to offer prayers on the grave and were shocked ...
Cached Medicine News:Health News:Scientists Develop Non-Toxic, Food Safe Paint 2Health News:China’s AIDS vaccine-successfully finishes first phas 2Health News:Police Stumble into Trading Corpses Racket 2
... Sun Med TruFlow™ Oxygen flowmeter with a ... warranty covering calibration and manufacturing defects. A ... meet most needs. Also available with all ... power take-off and double unit configurations. Our ...
... adults, the entire series of time-tested Timeter® ... the needs of care providers and patients ... accuracy. You can see it in the ... performance, year after year. Every Timeter® Classic ...
The Soft-Touch Timeter® Flowmeter is durable, long-lasting and easy to maintain. Timeter ® by Allied Flowmeters: Quality Plus Value....
The Soft-Touch Timeter® Flowmeter is durable, long-lasting and easy to maintain. Timeter ® by Allied Flowmeters: Quality Plus Value....
Medicine Products: